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Abstract
Cystic fibrosis (CF) is a genetic disease associated with
specific gene mutations that presents with pulmonary inflammation and frequent lung infections, exocrine pancreatic
insufficiency, altered sweat composition and declining lung
function. Ivacaftor (Kalydeco®) was approved for treatment
of cystic fibrosis in patients 6 years of age and older with a
G551D mutation on the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Ivacaftor is a CFTR potentiator and does not work in patients with a mutation of the
F508del. Efficacy has been demonstrated in several trials
with a primary outcome of improved FEV1, improvements in
pulmonary exacerbations, patient-reported decrease in respiratory symptoms and weight gain. Side effects that have
been reported include oropharyngeal pain, nasal congestion,
abdominal pain, upper respiratory tract infection, rash and
dizziness. The drug is metabolized via the CYP3A4 enzyme
system and should be monitored for potential drug interactions accordingly. Information on long-term safety is not yet
available, but clearly this drug represents an advance in the
management of a debilitating disease.

Introduction
On Jan. 31, 2012, Kalydeco® (ivacaftor) received FDA approval for treatment of cystic fibrosis (CF) in patients 6 years
of age and older with a GSSlD mutation on the cystic fibrosis
transmembrane conductance regulator (CFTR) gene. Cystic
fibrosis is a genetic disease that causes chronic pulmonary
inflammation, exocrine pancreatic insufficiency, altered
sweat composition and declining lung function. 1,2 This disease affects approximately 30,000 people in the United
States and 70,000 people worldwide.3 Diagnosis typically
occurs early in life, with approximately 70 percent of patients with CF diagnosed before 2 years of age.3 A variety of
CFTR mutations have been identified as causing CF.2 Ivacaftor is a CFTR potentiator that has shown efficacy in clinical trials for use in patients with at least one GSSlD mutation
on the CFTR gene.4,S However, clinical trials have shown that
ivacaftor is not effective in patients with a homozygous
FS08del mutation.6 Treatment options may vary between
individual patients due to the variety of genetic mutations
that may cause CF.2
Disease State Overview
Cystic fibrosis is an autosomal-recessive disease, requiring a
patient to have two mutated genes for the CFTR protein in
order to be affected by the disease. The CFTR protein is a
transmembrane protein present on the apical surface of exocrine epithelial cells, including cells in the lungs, pancreas
and sweat glands. This protein primarily acts as a chloride
channel, but it is also involved in the regulation of other ion
channels.2 More than 1,000 DNA mutations have been identi-

fied as causing CF, with different populations having higher
prevalence of specific mutations depending on race, ethnicity
and geographyP The most common mutation is F508del,
which is a deletion mutation resulting in improper folding of
the CFTR protein leading to little or no CFTR protein on the
cell surface. 6 Another mutation, called GSSlD, is a missense
mutation that prevents the binding of adenosine triphosphate (ATP) to the CFTR protein, resulting in an inability to
activate the CFTR protein.2 As of 2012, approximately 87
percent of people with CF were known to have at least one
copy of the F508del mutation, and approximately 4 percent
of people with CF had at least one copy of the GSSlD mutation.8 Because there are numerous genetic mutations that
can cause CF, the disease can vary in severity, pathogenesis
and treatment approach between individual patients.2
Symptoms of CF commonly include pulmonary inflammation,
recurrent respiratory infections, airway obstruction, exocrine pancreatic insufficiency and altered sweat composition.2·9 Defective CFTR proteins in the respiratory tract lead
to reduced chloride transport into the lumen, thereby decreasing surface water content and mucociliary clearance.
The heightened mucus retention leads to chronic respiratory
infections and inflammation, resulting in lung obstruction
and structural damage beginning in infancy, often before
symptoms are present.9 Pancreatic insufficiency is the decreased ability to digest nutrients in the gastrointestinal tract
with pancreatic enzymes. This occurs due to obstruction of
the pancreatic ducts and autoactivation of trypsin, a digestive
enzyme inside the pancreas, resulting in structural damage
to the pancreas. 10 Pancreatic insufficiency is present in many
phenotypes of CF, with more than 90 percent of diagnosed
CF patients beginning to exhibit low pancreatic function before 1 year of age. 11 Individuals affected by CF also typically
have a higher concentration of chloride in their sweat compared to individuals without CF.12
Screening for CF among newborns is becoming increasingly
common; however, diagnosis of CF can be difficult in some
patients. Multiple factors can serve as screening tools for CF.
A routine newborn screening (NBS) test in infants measures
levels of immunoreactive trypsinogen (!RT), a pancreatic
protein. A high concentration of !RT constitutes a positive
NBS for CF. Family history or presence of CF symptoms can
also be screening tools for this disease, as they identify patients who might be at risk for CF. A positive result in any of
these screening tests indicates that a patient needs to undergo diagnostic testing.12
The current diagnostic standard for CF is a sweat chloride
test. This involves collecting sweat from the patient after
stimulation of sweating, followed by comparing the resulting
chloride concentration to a standard. A chloride concentra-
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tion above 60 mmol/L is diagnostic for CF. Concentrations
between 40 mmol/L (or 30 mmol/L for patients under
6 months) and 60 mmol/L indicate the need for genotype
analysis to assess CFTR gene mutation. A chloride concentration below this range indicates that CF is very unlikely in the
patient. When the sweat test results in intermediate values,
the presence of two CF-inducing mutations is considered
diagnostic for CF. Genotype analysis is available but is not
preferred due to inaccuracy and difficult interpretation.1 2
Early diagnosis of CF is critical in order to begin treatment as
soon as possible to delay progression of the disease. 9
The aim of many current treatment options is to reduce pulmonary infections, exacerbations, inflammation and deterioration; compensate for pancreatic insufficiency by pancreatic
enzyme replacement therapy (PERT); and maintain healthy
nutrition and growth.11 Definitive treatment guidelines that
are applicable to all patients with CF are still needed; however, a majority of CF patients utilize a treatment regimen
including inhaled antibiotics, hypertonic saline, airway clearance techniques and bronchodilators.13 Inhaled antibiotics
aim to treat respiratory tract infections in CF patients, which
are commonly due to Pseudomonas aeruginosa. 11 Multiple
antibiotic options are available, including inhaled tobramycin, inhaled aztreonam and azithromycin. 11·13 Pulmonary exacerbations can be lessened by inhaled hypertonic saline in
patients over 6 years of age; however, this may not be
effective in patients under 6 years of age. 9 Airway clearance
therapy, such as percussion or postural drainage, is recommended for all patients.11 Inhaled ~z-agonists for bronchodilation may be used to reduce exacerbations, but evidence
supporting this therapeutic option is not strong.13 Pancreatic
insufficiency should be treated with PERT, even if evidence
of malabsorption is lacking. Following CF diagnosis, growth
and weight gain in infants should be promoted, as a higher
body mass index at 2 years of age is linked to improved lung
function in later childhood. Thus, proper nutrition and
growth should be lifelong therapeutic goals. 11 Additional
studies are needed to resolve questions of prioritizing the
importance of therapeutic options and identifying appropriate therapy options for patients less than 6 years of age.13
New treatment options continue to be explored in order to
better manage CF disease state.
Pharmacist Information and Counseling Points
Indication: lvacaftor, a CFTR potentiator, is a U.S. Food and
Drug Administration (FDA)-approved treatment option for
the management of CF in patients 6 years of age and
older.14.15 This particular CFTR potentiator is used specifically in patients who are found to have the G551D mutation
on the CFTR gene,14.15 It should be noted that ivacaftor is not
effective in treatment of patients with a homozygous mutation of the F508del mutation.is Ivacaftor works to repotentiate the nonfunctional CFTR transmembrane protein.
By increasing the chance of the CFTR being open, the regular
flux of chloride ions in epithelial cells is restored. 14.15 Due to
this normalization of flow, salt and water concentrations will
also be stabilized, leading to less viscous mucous secretions
and improved respiratory function.16
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Target Population: lvacaftor is targeting patients with a
G551D mutation of the CFTR protein.14,17 Pharmacological
treatment options for patients are limited to mucolytics, prophylactic antibiotics, bronchodilators and anti-inflammatory
medications.18 By using ivacaftor, patients may have enhanced therapy by targeting a more direct cause of symptoms instead of only providing symptomatic relief. Pediatric
patients are prime targets for CF treatment, and due to the
natural progression of the disease, the ability to start therapies in patients at an early age will be beneficial in reducing
the degenerative effects and long-term complications of CF.
lvacaftor, being approved for children ages 6 years of age
and older, has the potential to be at the forefront of CF pharmacotherapy.
Dosing: Kalydeco® is formulated as a "light blue capsuleshaped, film-coated tablet for oral administration."14 After
clinical studies, the most effective dose was established at
150 mg twice daily. 14 Adult dosing is also recommended for
pediatric patients due to similar pharmacokinetics.14 The
adherence to a high-fat diet while using ivacaftor helps to
increase medication absorption approximately twofold to
fourfold.17
Side Effects: Adverse reactions observed in over 10 percent
of patients are as follows: oropharyngeal pain, nasal congestion, abdominal pain, upper respiratory tract infection and
rash.15 Some patients have reported feeling dizzy after taking
ivacaftor, so it is advised that patients refrain from operating
heavy machinery until aware of how they are personally affected by the drug.17
Drug Interactions: Because ivacaftor is metabolized via the
CYP3A4 enzyme, it is important to be aware of the potential
effects of taking other medications which also interact with
CYP3A4. A brief guide to drug interactions and dosing adjustments related to changes in medication exposure may be
found in the manufacturer's treatment guide.17
Monitoring Parameters: There are several measurements
that can be monitored to demonstrate the positive effects of
ivacaftor. Such factors include an increase in forced expiratory volume (FEV), decreased respiratory exacerbations, decreased sweat chloride concentration, an increase in body
weight and an overall decrease in CF-like symptoms. Increases in alanine aminotransferase (ALT) or aspartate
amino transferase (AST) have been observed in ivacaftor
patients. Alanine aminotransferase and AST levels should be
assessed prior to treatment, then "every three months during
the first year of treatment, and annually thereafter."11 If elevations occur, it is recommended that the patients be monitored monthly if treatment benefit outweighs risk or until
numbers return to normal; however, if ALT and/or AST levels are greater than five times the normal upper limit, the
drug should be discontinued and therapy should be reevaluated.19,17
Patient Expectations: Patients can expect to see positive
results after less than a month of taking ivacaftor. They
should notice a decrease in sputum production, easier
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breathing patterns and an increase in weight gain.17 Because
CF is a chronic disease, their medication regimen will also be
chronic, and patients should be made aware that ivacaftor is
not a "cure" for CF.

and suggests that the drug is safe for this subpopulation.24
These four clinical trials are key to understanding the therapeutic benefit of ivacaftor in patients with CF containing the
GSSlD mutation.

How to Improve Compliance: While chronic medication
regimens may seem overwhelming, it is important to stress
the benefits of high adherence. In assessing the willingness of
pediatric patients to follow their CF therapy, roughly half
have been estimated to be noncompliant.20 One benefit to
using ivacaftor is the ability to see results in a relatively short
period of time after initiation of therapy compared to longterm methods such as airway clearance techniques.21 Seeing
quick results will help patients to continue therapy, as "no
perceived benefit" has been identified as one of the barriers
to effective treatment.22 Furthermore, parental involvement
is a highly important aspect in pediatric care. In fact, parents
may even be seen as part of the health care team due to their
role in facilitating and assisting their child in following CF
treatment protoco1.22 Therefore, counseling the primary
caregiver will be just as important as counseling the pediatric patient. This being said, pharmacists should be able to
recognize their own role in this education process. A single
case study designed by McClellan, Cohen, and Moffett intending to increase pediatric compliance to CF therapy, attempted the use of a "time out" technique when children resisted compliance.23 Time out may be generalized to the
strategy of, "removing the child from reinforcers and reinforcing environments upon noncompliance with demands,"
and was shown to decrease behavioral conflicts with CF therapy. One given example of time out would be placing a child
in a chair facing the wall for several minutes without permission to talk to others.23 While this method of intervention
may seem rudimentary, it demonstrates how reinforcing and
encouraging children to adhere to CF therapy can be quite
practical.

Ramsey et al. conducted the main efficacy trial supporting
the use of ivacaftor for improved lung function in patients
with CF containing the GSSlD mutation. The study was a 48week, phase III clinical trial. Eligible patients for this trial
included those aged 12 years or older who had a previous
diagnosis of CF, possessed the GSSlD mutation on at least
one CFTR allele, and had an FEV1 between 40 and 90 percent
of the predicted value given age, sex and height. No specific
exclusion criteria were provided. The primary endpoint for
the trial was the absolute change in FEV1 from baseline at
week 24. Secondary endpoints included change in FEV 1 from
baseline at week 48, the time to pulmonary exacerbation,
patient reported respiratory symptoms, weight change and
CFTR function (via sweat chloride test).4

Cost: As of Nov. 6, 2013, the average wholesale price of 60
(150 mg) tablets (one month's supply) of ivacaftor is
$30, 723.60.15 Therefore, the high cost of this medication may
be a barrier in effective treatment for some patients.

Literature Review
Several clinical trials have been conducted that support the
approval of ivacaftor for the treatment of CF containing the
G551D mutation, while also possessing a manageable side
effect profile. The first is a phase III clinical trial concluding
that the utilization of ivacaftor led to a statistically significant
increase in pulmonary function in patients over the age of 12
as defined by forced expiratory volume in one second
(FEV1).4 The next study is a phase III clinical trial concluding
a similar increase in pulmonary function as defined by FEV 1
in pediatric subjects between the ages of 6 and 11.S The third
study is a phase II clinical trial assessing the safety and function of ivacaftor in CF that is homozygous for the F508del
mutation concluding that ivacaftor, while reasonably safe, is
not effective in this subpopulation. 6 The final study is a phase
II clinical trial that provides a look into the safety profile of
ivacaftor in patients with CF containing the GSSlD mutation,
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In the study, 161 patients were randomly assigned to one of
two treatment groups: ivacaftor 150 mg twice daily (n=83)
or placebo (n=78). The randomization was stratified for both
age ( <18 years or :2:18 years) and baseline pulmonary function ( <70 percent or ~70 percent predicted FEV 1 level). The
stratification process was successful; lending equally distributed demographics across the two treatment groups. Power
calculations had concluded that 160 patients would provide
80 percent power to detect a change of 4.5 percent in the
predicted FEV 1. All patients received their medications twice
daily for a full 48 weeks and were allowed to remain on all
other medications with an FDA-approved indication for CF,
such as dornase alfa and inhaled antibiotics. Primary outcome was assessed for all patients at week 24 and secondary
outcomes were assessed for all patients at day 15, week 24,
and week 48.4
At week 24, patients in the ivacaftor group witnessed a 10.4
percent increase in FEV1 compared to a 0.2 percent decrease
in the placebo group (p<0.001). The effect on FEV1 was noted
to be statistically significant at day 15, and was retained
throughout all 48 weeks of treatment. This change in FEV 1
was analyzed over subgroups defined by baseline FEV 1, age
and sex; there was no apparent difference in the efficacy of
ivacaftor with respect to change in FEV1 across any of these
different subgroups. In addition to change in baseline FEV 1,
other outcomes such as pulmonary exacerbations (p=0.001),
patient reported respiratory symptoms (p<0.001), weight
gain (p<0.001) and CFTR function (p<0.001) were all improved in the ivacaftor treatment group.4
Overall, patients in the placebo group experienced more adverse events than patients in the ivacaftor group, likely due
to the decreased level of pulmonary exacerbation in patients
treated with ivacaftor. Forty-two percent of subjects in the
placebo group experienced a serious adverse event while
only 24 percent of subjects in the ivacaftor group experienced such an event. However, two patients in the ivacaftor
group experienced hypoglycemia while no patients in the
placebo group experienced this adverse event. The study
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yielded no adverse events that were concluded to have
arisen as a result of ivacaftor treatment. All patients who
were initiated on either of the treatment drugs completed
the trial with the exception of one subject, a member of the
placebo group who dropped out of the study following a severe pulmonary exacerbation. Ultimately, ivacaftor was not
associated with any significant adverse events not seen in the
placebo group.4
Limitations of this trial include restrictive inclusion criteria
and limited documentation on use of other CF medications.
The inclusion criteria only allowed patients who were between 40 and 90 percent of predicted FEV1 levels. 4 This prevents the most critical of patients from enrolling in the study,
limiting the external validity of the trial. It must also be noted
that the trial utilized ivacaftor only as add-on therapy to an
established CF treatment regimen. The protocol did require
that patients be on their current medication regimen for a
full year prior to trial initiation, but it is unclear what effect
the impact that those drugs may or may not have on the efficacy value of ivacaftor.4
The second main efficacy trial, by Davies et al., is a 48-week
phase III study conducted in children aged 6 to 11. Eligible
patients for this trial included children aged 6 to 11 with a
confirmed diagnosis of CF containing the G551D mutation.
Additionally, subjects were required to have a predicted
FEV1 between 40 and 105 percent given their age, sex and
height. The primary endpoint for the study was absolute
change in FEV1 from baseline at week 24. Secondary endpoints included change in FEV1 from baseline at week 48,
weight change, CFTR function (via sweat chloride tests), patient and parent reported respiratory symptoms, and safety. 5
In the study, 52 patients were randomly assigned to one of
two treatment arms: placebo (n=26) or ivacaftor 150 mg
twice daily (n=26). There was no randomization stratification or power calculation. All patients received their treatment medication twice daily for a full 48 weeks and were
allowed to remain on all medications that possessed an FDAapproved indication for CF. Endpoints were assessed at follow-up meetings every eight weeks (weeks 8, 16, 24, 32, 40,
and 48) in addition to day 15.s
With regard to change in baseline FEV1 at week 24, the ivacaftor group witnessed an increase of 12.6 percent compared
to an increase of 0.1 percent in the placebo group (p<0.001).
This statistically significant effect was noted at day 15 and
was maintained throughout the course of the clinical trial to
the week-48 endpoint. Other secondary outcomes that
showed improvement in the ivacaftor treatment group compared to the placebo group included weight gain (p<0.001),
patient and parent reported respiratory symptoms (p=0.109;
p=0.033) and CFTR function (p<0.001).s
The total incidence of adverse events was similar between
the two treatment groups. The ivacaftor group experienced
the following side effects more often than the placebo group:
oropharyngeal pain, headache, nasopharyngitis, upper respiratory tract infection, otitis media, diarrhea and increased

Pediatrics

blood eosinophil count. Serious adverse events such as pulmonary exacerbation and productive cough were witnessed
infrequently with no difference between treatment groups.
These results mimic those seen in the adult clinical trials and
suggest that ivacaftor is well-tolerated in the pediatric population aged 6 and above.s
The main limitation of this trial is a clear lack of power. This
inadequacy is quite common in pediatric clinical trials due to
a multitude of factors including, but not limited to, the low
incidence of CF and parental concern over experimental
treatments. Even so, the lack of power must be considered
when trying to determine the external validity of the trial.
The third efficacy trial, conducted by Flume et al., is a 16week (followed by a 96-week open-label extension period)
phase II study. Eligible patients for this trial included clinically stable subjects over the age of 12 who had been diagnosed with CF containing two F508del alleles (homozygous).
Additionally, subjects were required to have a predicted
FEV1 above 40 percent given their age, sex and height. Subjects remained on their pre-study medication regimens
throughout the study with the exception of hypertonic saline
and known inducers/inhibitors of CYP3A4. The primary endpoints for the study were (1) absolute change in FEV1 from
baseline at week 16 and (2) safety as evaluated by adverse
events, lab values, vital signs and physical examinations.6
In the study, 140 patients were randomly assigned in a 1:4
ratio to one of two treatment arms: placebo (n=28) or ivacaftor 150 mg twice daily (n=112). There was no randomization stratification or formal power calculation. All patients
received their treatment medication twice daily for a full 48
weeks and were allowed to remain on all medications that
possessed an FDA-approved indication for CF. Endpoints
were assessed at follow-up meetings every eight weeks (8,
16) in addition to day 15. Any patient who experienced a
greater than 10 percent increase in FEV1 at any time point
during the 16-week treatment period qualified to enroll in
the 96-week open-label extension.6
With regard to change in baseline FEV1 at week 16, the ivacaftor group witnessed an increase of 1.7 percent compared
to placebo, which was not statistically significant (p=0.15).
Twenty-eight members of the ivacaftor group (25%) and six
members of the placebo group (21.4%) qualified for the
open-label extension period as a result of their increased
FEV1. The difference in FEV1 was not statistically significant
in these patients at the conclusion of the open-label extension (p=0.46).6
The overall safety profile was similar in both treatment arms.
However; cough, nausea, rash and contact dermatitis occurred more often in the ivacaftor group; none of these
events was considered severe. On the other hand, pulmonary
exacerbation occurred more often in the placebo group. Few
members of the ivacaftor group experienced life-threatening
events including fatigue, depression and suicidal ideation
(n=l; 0.9%) as well as severe events including nasal congestion, epistaxis, diarrhea, rash, headache, and arthritis (n=lO;
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8.9%). Three subjects (2.7%) in the ivacaftor group discontinued the study drug due to adverse events.6
This study allows for the conclusion that ivacaftor is not effective in patients homozygous for the FSOBdel mutation.
The study does, however, provide additional information
regarding the safety of ivacaftor in patients with diagnosed
CF. The adverse event profile witnessed in this study supports the conclusion that ivacaftor is well-tolerated in patients over the age of 12 diagnosed with CF.
The final trial, conducted by Accurso et al., is a phase II study
designed to assess the safety and adverse event profile of
ivacaftor in patients who have CF containing the GSSlD mutation. Eligible patients for this trial included patients over
the age of 18 who had been diagnosed with CF and possessed
a GSSlD mutation on at least one CFTR allele; patients also
had to have an FEV1 of 40 percent or more of the estimated
level for age, sex and height. No specific exclusion criteria
were reported. The primary endpoint for the study was to
assess the safety and adverse event profile of ivacaftor. Secondary endpoints included markers of CFTR function (nasal
potential difference and sweat chloride concentration), pulmonary performance (FEV1) and quality of life (Cystic Fibrosis Questionnaire-revised; CFQ-R).24
This trial was designed as a two-part study. In part one, 20
subjects were placed into one of five treatment groups: placebo (n=4), ivacaftor 25/75 mg (n=4), ivacaftor 75/25 mg
(n=4), ivacaftor 75/150 mg (n=4), and ivacaftor 150/75 mg
(n=4), where the first strength indicates the dose received
prior to a 14-day washout period and the second strength
indicates the dose received after the washout period. Subjects were given their initial treatment dose twice daily for
14 days; a 14-day washout period followed; subjects were
then given their second treatment dose twice daily for an
additional 14 days. Primary and secondary endpoints were
assessed for all patients at the end of each 14-day treatment
period. In part two, 19 subjects (different from the participants in part one) were placed into one of three treatment
groups: placebo (n=4), ivacaftor 150 mg (n=B), ivacaftor
250 mg (n=7). Subjects were given their treatment doses
twice daily for a continuous 28 days after which primary and
secondary endpoints were assessed.24
The primary outcome for both part one and part two of this
clinical trial yielded relatively few side effects associated
with the use of ivacaftor at any dosage strength. There were
22 reported instances of drug-associated moderate or severe
adverse events. Some of the more prominent adverse events
that were reported included elevated blood glucose, body
aches, glycosuria and nausea. Secondary efficacy outcomes
yielded no statistical significance over placebo.24 However,
the low enrollment of the study combined with a lack of
power make the lack of statistical efficacy over placebo a
moot point.
These four trials outline the safety and efficacy data that is
currently available for the use of ivacaftor in humans. However, it must also be noted that all four of these clinical trials

were both funded and designed by the manufacturer of ivacaftor, Vertex Pharmaceuticals™, but given the infancy of the
compound, orphan nature of the drug in question and the
fact that these were the clinical trials involved in the FDA
approval process for the medication; this manufacturerdriven study process is an economic necessity. Furthermore,
the transparency with which the authors addressed their
potential conflicts of interest limits any potential concern for
bias. An additional point to consider is that given the genetic
nature of CF, pulmonary function can begin to decrease well
before age 6, meaning that these undeveloped patients are in
a prime position to alter the course of their disease. It would
be beneficial to see a clinical trial in patients younger than
age 6, in order to determine if ivacaftor can maintain its thusfar impressive clinical impact on a younger set of patients.
Currently, Vertex Pharmaceuticals™ is recruiting for a phase
III clinical trial to assess the safety and efficacy of ivacaftor in
patients aged 2 to 5.25
Ultimately, while the G551D mutation impacts less than
10 percent of all patients with a CF diagnosis, the success for
ivacaftor with regard to improvement of clinical indicators in
this subpopulation is a definitive step forward. In particular,
consistent double-digit improvement of FEV1 suggests a significant boost in lung function when compared to other commonly used CF therapies. 4 Unfortunately, it remains to be
seen what long-term impact ivacaftor may have on lifeexpectancy and long-term quality oflife in patients with CF.
Conclusion
Kalydeco® (ivacaftor) has been approved for the treatment
and management of CF in pediatric patients as of Jan. 31,
2012. This medication is approved for patients
6 years of age and older, who have a G551D mutation on the
CFTR gene.14,15 Ivacaftor's novelty comes from its genetic
specificity for the aforementioned CF mutation.14,15 Because a
majority of CF patients are diagnosed before they reach the
age of 2, it is important to have medication therapy protocols
approved and at the ready for children.3 Short-term effects
have shown promise with increasing FEY1 values; however,
information on long-term use is uncertain. Overall, introduction of ivacaftor into medication regimens is a positive step
for the treatment of pediatric patients living with cystic
fibrosis.
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